USA flag logo/image

An Official Website of the United States Government

Nicotine delivery to rodent with lung alveolar region-targeted aerosol…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2013 / SBIR
Agency Tracking Number:
R44DA031578
Solicitation Year:
2013
Solicitation Topic Code:
NIDA
Solicitation Number:
PA12-088
Small Business Information
AFASCI, INC.
522 Second Avenue REDWOOD CITY, CA 94063-3848
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2013
Title: Nicotine delivery to rodent with lung alveolar region-targeted aerosol technology
Agency: HHS
Contract: 2R44DA031578-02
Award Amount: $990,659.00
 

Abstract:

DESCRIPTION (provided by applicant): Our completed SBIR Phase I project (R43 DA031578) was in response to NIH PA11-096, PHS 2011-02 'Omnibus solicitation for SBIR/STTR Grant Application' under NIDA 2, Development of Alternate Drug Delivery Dosage Forms for Drugs Abuse Studies. We have developed an alveolar region-targeted aerosol/inhalation method for nicotine delivery to rodents and developed devices with specialized software that enable this new method to be used effectively. In both the nose-only device and free-moving exposure chambers, the aerosol droplet size distribution is within the respirable diameter range. By physically imitating the properties of cigarette smoke, aerosol inhalation produces nicotine PK in both the arterial and venous blood resembling the PK profile of humans smoking cigarettes. This noninvasive method overcomes the limitations of current nicotine delivery methods. We have demonstrated that this novel method and device enable rapid delivery of a controllable amount of nicotine into systemic circulation and induces dose-dependent behavioral responses. The goal of this Phase II project is to translate the prototypes into commercialized products- AeroDeliver(R) . Three Specific Aims are as follows: Aim 1. Develop and scale up a commercial product series of integrated aerosol inhalation systems including nose-only exposure devices and free-moving exposure chambers. We will create the integrated hardware and software, and scale up to simultaneously operate 16 AeroDeliver(R) systems. Aim 2. Further develop the novel alveolar region-targeted aerosol inhalation method for chronic intermittent nicotine exposure and validate it with animal testing. The device and protocol will be evaluated and validated using animal testing and by measuringplasma nicotine concentrations that simulate the PK profile in moderate to heavy human smokers. We will verify nicotine aerosol deposition in the lungs in vivo by positron emission tomography (PET) with radioactive labeled nicotine aerosol. Aim 3. Establish nicotine aerosol self-administration paradigms in drug dependence and reinforcement studies. The system will have positive and negative levers (for rats) or nosepoke sensors (for mice) for performance choice. The system will also perform fixed ratio (FR)and progressive ratio (PR) reinforcement schedules. We will evaluate the system in rodent experiments and compare the operation and results with conventional i.v. nicotine self-administration methods that use currently available commercial devices. In thecourse of animal testing, we will also develop an experimental cookbook with standardized protocols to facilitate comparison of results generated by different laboratories. Our products -AeroDeliver(R) system will be a powerful toolkit for studies of nicotine addiction, toxicology, teratogenicity and tobacco-related diseases, and ultimately, for facilitation of new therapeutic discovery. Furthermore, the significant potential for these toolkits to be used for other drugs of abuse such as marijuana, cocaine, and heroin will expand the market size for our products. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: We are developing an alveolar region-targeted aerosol/inhalation method and devices for nicotine delivery to rodents. Aerosol inhalation produces nicotine concentrations in the blood resembling human smoking cigarettes. Our products -AeroDeliver(R) system is a powerful toolkit for studies of nicotine addiction, toxicology, teratogenicity and tobacco-related diseases, and ultimately, for facilitating discovery of new therapeutics.

Principal Investigator:

Xinmin S. Xie
650-995-7320
simonxie@afasci.com

Business Contact:

Xiaosu S. Li
650-219-8199
sueli@afasci.com
Small Business Information at Submission:

AFASCI, INC.
522 Second Avenue REDWOOD CITY, CA -

EIN/Tax ID: 177060565
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No